Developing non-viral DNA delivery systems for cancer and infectious disease

Drug Discovery Today

Volumn 6, Issue 4, 2001, Pages 186-197

  Spack, Edward G ^a   Sorgi, Frank L ^b  

^a InterMune Pharmaceuticals   (United States)

^b OPTIME Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; B7 ANTIGEN; CD86 ANTIGEN; CYTOKINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPID; LIPOFECTIN; LIPOSOME; N [1 (2,3 DIOLEOYLOXY)PROPYL] N,N,N TRIMETHYLAMMONIUM CHLORIDE; PLASMID DNA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER PREVENTION; CYTOKINE RELEASE; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; ELECTROPORATION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INFLUENZA; MALARIA; NONHUMAN; NUCLEOTIDE SEQUENCE; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 0035254223     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01633-0     Document Type: Review

References (100)

1. Gene therapy - promises, problems and prospects
2. Adenovirus vectors for gene delivery
3. Direct gene transfer into mouse muscle in vivo
4. CpG islands as gene markers in the vertebrate nucleus
5. The role of CpG motifs in innate immunity
6. Antitumor activity of deoxyribonucleic acid fraction from mycobacterium bovis GCG. I. Isolation, physicochemical characterization, and antitumor activity
7. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
8. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity
9. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
10. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
11. Promoter attenuation in gene therapy: causes and remedies
12. Interferon-γ inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter
13. Promoter attenuation in gene therapy: interferon-γ and tumor necrosis factor-α inhibit transgene expression
14. Towards gene therapy for cystic fibrosis: a clinical progress report
15. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung
16. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid-cationic lipid complexes
17. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid-pDNA complexes
18. Liposomal gene delivery - a complex package
19. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipid vectors
20. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously
21. Liposome-mediated, non-viral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation
22. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs
23. Toxicity of cationic liposome-DNA complexes in lung isografts
24. Genetic immunization is a simple method for eliciting an immune response
25. Heterologous protection against influenza by injection of DNA encoding a viral protein
26. DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigens
27. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
28. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity
29. Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination
30. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
31. Costimulatory B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen
32. Selected strategies to augment polynucleotide immunization
33. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development
34. Manipulation of the immune-response to a plasmid-encoded viral antigen by co-inoculation with plasmids expressing cytokines
35. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids
36. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines
37. DNA vaccines: a review
38. DNA vaccines: immunology, application and optimization
39. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice
40. Improved encapsulation of DNA in pH-sensitive liposomes for transfection
41. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure
42. Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications
43. Cationic liposome mediated gene transfer
44. An electron microscopy study into the mechanism of gene transfer with lipopolyamines
45. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes
46. Cellular and molecular barriers to gene transfer by a cationic lipid
47. Mechanism of DNA release from cationic liposome-DNA complexes used in cell transfection
48. Potentiation of cationic liposome-mediated gene delivery by polycations
49. Protamine sulfate enhances lipid-mediated gene transfer
50. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers
51. The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes
52. DNA transfection in COS cells: a low-cost serum-free method compared to lipofection
53. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability
54. Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine
55. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle
56. Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood
57. Use of plasmid DNA for direct gene transfer and immunization
58. Direct transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression
59. DNA vaccines - a modern gimmick or a boon to vaccinology?
60. Electropermeabilization of skeletal muscle enhances gene transfer in vivo
61. High-efficiency gene transfer into skeletal muscle mediated by electric pulses
62. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo
63. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells
64. Gene vaccination with naked plasmid DNA: mechanism of CTL priming
65. Immune-mediated destruction of transfected muscle fibers after direct transfer from myocytes
66. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles
67. Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory
68. DNA-based immunization by in vivo transfection of dendritic cells
69. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope
70. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells
71. Influenza virus nucleoprotein specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery
72. Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses
73. DNA and RNA-based vaccines: principles, progress and prospects
74. Manipulation of HIV-1 gp120-specific immune responses elicited via gene gun-based DNA immunization
75. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts
76. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles
77. A novel method for DEAE-dextran mediated transfection of adherent primary cultured human macrophages
78. Receptor-mediated gene transfer into macrophages
79. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction
80. DNA immunization with minigenes: low frequency of memory CTL and inefficient antiviral protection are rectified by ubiquitination
81. Enhancing DNA immunization
82. DNA vaccines for viral diseases
83. DNA vaccines
84. The prime-boost strategy: exciting prospects for improved vaccination
85. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
86. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
87. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria NA vaccine
88. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
89. DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees
90. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
91. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response
92. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity and lack of toxicity in humans
93. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial
94. DNA vaccines against cancer: from genes to therapy
95. Colorectal cancer vaccines
96. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity
97. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma